Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Chad Orevillo"'
Autor:
Colin Reisner, Gregory Gottschlich, Faisal Fakih, Andras Koser, James Krainson, Luis Delacruz, Samir Arora, Gregory Feldman, Krishna Pudi, Shahid Siddiqui, Chad Orevillo, Andrea Maes, Earl St. Rose, Ubaldo Martin
Publikováno v:
Respiratory Research, Vol 18, Iss 1, Pp 1-11 (2017)
Abstract Background Symptoms of chronic obstructive pulmonary disease may vary throughout the day and it is important that therapeutic approaches provide 24-h symptom control. We report the results of two phase IIIb crossover studies, PT003011 and PT
Externí odkaz:
https://doaj.org/article/411f6d54c236445c801f43ed633faa2b
Autor:
Colin Reisner, Leonardo M. Fabbri, Edward M. Kerwin, Charles Fogarty, Selwyn Spangenthal, Klaus F. Rabe, Gary T. Ferguson, Fernando J. Martinez, James F. Donohue, Patrick Darken, Earl St. Rose, Chad Orevillo, Shannon Strom, Tracy Fischer, Michael Golden, Sarvajna Dwivedi
Publikováno v:
Respiratory Research, Vol 18, Iss 1, Pp 1-3 (2017)
Externí odkaz:
https://doaj.org/article/17498a261b56421cb7b43b3ee787e347
Autor:
Leonardo M. Fabbri, Patrick Darken, Fernando J. Martinez, Gary T. Ferguson, Ubaldo J. Martin, Chad Orevillo, Colin Reisner
Publikováno v:
Chest. 152:1169-1178
Background The clinical severity of COPD is currently categorized by symptom burden and exacerbation risk. Previous 24-week phase III trials (NCT01854645 and NCT01854658) that demonstrated better improvement of lung function with glycopyrrolate/formo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3db5984b01bfe7a6707c93758b7b69d9
https://doi.org/10.1016/j.chest.2017.07.007
https://doi.org/10.1016/j.chest.2017.07.007
Autor:
Shahid Siddiqui, Gary T. Ferguson, Selwyn Spangenthal, Patrick Darken, Gregory Gottschlich, Tracy Fischer, Chad Orevillo, Fernando J. Martinez, Thomas Siler, Colin Reisner, Michael Golden, Leonardo M. Fabbri, Roberto Rodriguez-Roisin, Samir Arora, Andrea Maes, Klaus F. Rabe, Stephen I. Rennard, Sanjay Sethi, Gregory Feldman
Publikováno v:
Chest. 151:340-357
Background Long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA) combinations are a treatment option for patients with COPD who continue to have symptoms despite treatment with a LAMA or a LABA alone. The Efficacy and Safety of PT00
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97f7b89621d2f35cf5d62171dac975f9
https://doi.org/10.1016/j.chest.2016.11.028
https://doi.org/10.1016/j.chest.2016.11.028
Autor:
Charles Fogarty, Sanjay Sethi, Shannon Strom, Michael Golden, Fries M, Patrick Darken, Stephen I. Rennard, Tracy Fischer, Colin Reisner, Fernando J. Martinez, Sarvajna Dwivedi, Chad Orevillo, St Rose E, Nicola A. Hanania
Publikováno v:
Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation. 4:21-33
Background: Co-Suspension™ Delivery Technology offers a novel pharmaceutical platform for inhaled drug therapy. This randomized, double-blind, placebo-controlled, single-dose study (NCT01349868) evaluated the efficacy of a range of doses for formot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c4d68568c93fbfdeb30a51956a6754d
https://doi.org/10.15326/jcopdf.4.1.2016.0158
https://doi.org/10.15326/jcopdf.4.1.2016.0158
Autor:
Colin Reisner, Roberto Rodriguez-Roisin, Mark Gotfried, Tracy Fischer, Shannon Strom, Earl St Rose, Chad Orevillo, Michael Denenberg, Gregory Gottschlich, Charles Fogarty, Donald P. Tashkin, Michael Golden, Patrick Darken, James F. Donohue, Fernando J. Martinez
Publikováno v:
Respiratory Medicine. 120:16-24
Background This study formed part of the dose selection for a glycopyrrolate (GP)/formoterol fumarate (FF) fixed-dose combination formulated using novel Co-Suspension™ Delivery Technology and delivered via a metered dose inhaler (GFF MDI). The stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92b5d42e82f3f8f8b790745771b53e31
Autor:
Ubaldo J. Martin, Sarvajna Kumar Dwivedi, Lauren Mello, Andrea Maes, Mark Sommerville, Simon Warren, Glyn Taylor, Chad Orevillo, Omar S. Usmani
This gamma scintigraphy imaging study was the first to assess pulmonary and extrathoracic deposition and regional lung deposition patterns of a radiolabelled long-acting muscarinic antagonist/long-acting β2-agonist fixed-dose combination glycopyrron
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::330b1d397b6036b2b2b254e90a7b564a
http://hdl.handle.net/10044/1/55069
http://hdl.handle.net/10044/1/55069
Autor:
Sarvajna Kumar Dwivedi, Fernando J. Martinez, Patrick Darken, Gary T. Ferguson, Leonardo M. Fabbri, Colin Reisner, James F. Donohue, Edward Kerwin, Charles Fogarty, Selwyn Spangenthal, Chad Orevillo, Michael Golden, Shannon Strom, Tracy Fischer, Klaus F. Rabe, Earl St Rose
Publikováno v:
Respiratory Research
Respiratory Research, Vol 18, Iss 1, Pp 1-3 (2017)
Respiratory Research, Vol 18, Iss 1, Pp 1-3 (2017)
Background Long-acting muscarinic antagonist/long-acting β2-agonist combinations are recommended for patients whose chronic obstructive pulmonary disease (COPD) is not managed with monotherapy. We assessed the efficacy and safety of glycopyrrolate (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::102c01af522538b5131dd0f35a073bc0
https://pubmed.ncbi.nlm.nih.gov/28061907
https://pubmed.ncbi.nlm.nih.gov/28061907
Autor:
Gregory Gottschlich, James Krainson, Andrea Maes, Shahid Siddiqui, Faisal Fakih, Luis Delacruz, Chad Orevillo, Krishna Pudi, Colin Reisner, Samir Arora, Gregory Feldman, Andras Koser, Earl St Rose, Ubaldo J. Martin
Publikováno v:
Respiratory Research
Respiratory Research, Vol 18, Iss 1, Pp 1-11 (2017)
Respiratory Research, Vol 18, Iss 1, Pp 1-11 (2017)
Background Symptoms of chronic obstructive pulmonary disease may vary throughout the day and it is important that therapeutic approaches provide 24-h symptom control. We report the results of two phase IIIb crossover studies, PT003011 and PT003012, i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33f1d21e5d8c998cd99b6f4e2add8795
https://pubmed.ncbi.nlm.nih.gov/28821260
https://pubmed.ncbi.nlm.nih.gov/28821260
Autor:
Edward Kerwin, Charles Fogarty, Sarvajna Dwivedi, Klaus F. Rabe, Earl St Rose, Chad Orevillo, Fernando J. Martinez, Patrick Darken, Selwyn Spangenthal, Shannon Strom, Gary T. Ferguson, Colin Reisner, Tracy Fischer, Leonardo M. Fabbri, James F. Donohue, Michael Golden
Long-acting muscarinic antagonist/long-acting β2-agonist combinations are recommended for patients whose chronic obstructive pulmonary disease (COPD) is not managed with monotherapy. We assessed the efficacy and safety of glycopyrrolate (GP)/formote
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5d87279ba7746e248f0d7b10c1678fb